AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04797936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
Study NCT00575601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
Study NCT00575601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SIMVASTATIN
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
Study NCT00897676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exendin-(9-39)
Description: 100-500pmol/kg/min
Study NCT00897676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo (0.9% NaCl)
Study NCT04461587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: see previous entries
Study NCT03750357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Relief v 2.0
Description: To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
Study NCT00751023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400 mg daily for four weeks
Study NCT00751023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets daily for 4 weeks
Study NCT01707316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin 100 mg
Description: Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
Study NCT01707316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin 300 mg
Description: Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
Study NCT01707316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo
Description: Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
Study NCT03199365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Undergo TSSC intervention sessions
Study NCT03199365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Undergo TSSC intervention sessions
Study NCT03537729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient Cues
Description: Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
Study NCT03537729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Education
Description: Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
Study NCT00864227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation
Description: The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1
Study NCT00864227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days.
Study NCT04416776 — intervention group
Intervention type: DRUG
Intervention: Strabismus diagnostic system.
Description: An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
Study NCT03074175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
Study NCT03596125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine supplementation
Study NCT03596125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os: jelly tablets Intravenous Route: Glucidion G5
Study NCT00616239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20-30% Salicylic Acid peels to the right side of the face
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
Study NCT00616239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20-30% Salicylic Acid peels to the left side of the face
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
Study NCT02688114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline surveillance endoscopy
Description: All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
Study NCT02688114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: All study participants will undergo radiofrequency ablation of Barrett's esophagus
Study NCT00796354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVICOL
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Study NCT00796354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Study NCT01558414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS Cholecystectomy
Description: Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
Study NCT01558414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FSIS cholecystectomy
Description: Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
Study NCT01558414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopy
Description: Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
Study NCT04452162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
Study NCT02688114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 1
Description: All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
Study NCT02688114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 2
Description: All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
Study NCT02688114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow up endoscopy 3
Description: All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
Study NCT01572623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
Study NCT01572623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
Study NCT03717701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Patients will take metformin single dose of 1000 mg orally once a day
Study NCT03717701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Patients will take esomeprazole single dose of 40 mg orally once a day
Study NCT03230487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Study NCT03717701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take inert tablets similar in appearance, color, and consistency
Study NCT03595436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-20g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study NCT03595436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-30g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study NCT03595436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Protein-40g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study NCT03839433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide
Study NCT03839433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Study NCT03595436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein-20g
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study NCT03595436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Control
Description: The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
Study NCT02387762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Study NCT02387762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00163722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Culture and histology
Study NCT00163722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspergillus galactomannan and PCR
Study NCT01558089 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: according to SmPC and clinical practice
Study NCT01558089 — intervention group
Intervention type: DRUG
Intervention: methotrexate
Description: according to SmPC and clinical practice
Study NCT01302769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard treatment plus ear acupuncture
Description: Standard treatment plus ear acupuncture
Study NCT03632512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium honey bolus
Description: The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
Study NCT03203642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablet; Route of administration: orally
Study NCT03203642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
Study NCT04837664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
Study NCT04837664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Bengal
Description: Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
Study NCT03632512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo honey bolus
Description: The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
Study NCT04569305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
Study NCT04569305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
Study NCT04837664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin
Description: Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
Study NCT00905008 — intervention group
Intervention type: PROCEDURE
Intervention: transluminal percutaneous coronary intervention
Description: All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
Study NCT00831896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-701
Description: Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy.
Study NCT02267525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag
Study NCT02267525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03816137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConM SOSIP
Description: Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study NCT02548468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT02548468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02548468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Donor Lymphocyte Infusion
Description: Undergo donor CD3+ enriched T lymphocyte infusion
Study NCT02033551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Study NCT02033551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03816137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EDC ConM SOSIP
Description: Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study NCT03816137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ConS UFO
Description: Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
Study NCT03816137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EDC ConS UFO
Description: Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study NCT02548468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02548468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSC transplant
Study NCT02548468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT02548468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study NCT02548468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT04387383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
Study NCT04387383 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-acupuncture
Description: Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
Study NCT01396330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stress
Description: 3 professional safe drive training courses each lasting 30 minutes